Allon Therapeutics Inc NPCUF

Healthcare Biotechnology

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).

GREY:NPCUF - Post by User

Allon Therapeutics Inc

Bullboard Posts

Post by diadon1945on Feb 16, 2011 2:05pm

282 Views

Post# 18144557

BIO CEO presentation very strong

You should have a look at it. Interesting information about PSP studies and potential $700 million(plus) market for this one indication alone.It is bigger than ALS or Huntington's. i did not know that.

Bullboard Posts

Rich TV Live’s Stocks to Watch this week (Nov. 15, 2024)